260 related articles for article (PubMed ID: 12624710)
21. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
[TBL] [Abstract][Full Text] [Related]
22. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.
Viñolas N; Molina R; Galán MC; Casas F; Callejas MA; Filella X; Grau JJ; Ballesta AM; Estape J
Anticancer Res; 1998; 18(1B):631-4. PubMed ID: 9584045
[TBL] [Abstract][Full Text] [Related]
23. IL-6 and VEGF in small cell lung cancer patients.
Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK
Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377
[TBL] [Abstract][Full Text] [Related]
24. Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles.
Keller T; Bitterlich N; Hilfenhaus S; Bigl H; Löser T; Leonhardt P
J Cancer Res Clin Oncol; 1998; 124(10):565-74. PubMed ID: 9829861
[TBL] [Abstract][Full Text] [Related]
25. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
26. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
27. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
28. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
29. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
Bitterlich N; Muley T; Schneider J
Anticancer Res; 2010 May; 30(5):1661-5. PubMed ID: 20592358
[TBL] [Abstract][Full Text] [Related]
30. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
31. Early diagnosis of lung cancer by detection of tumor liberated protein.
Tarro G; Perna A; Esposito C
J Cell Physiol; 2005 Apr; 203(1):1-5. PubMed ID: 15389637
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.
Miédougé M; Rouzaud P; Salama G; Pujazon MC; Vincent C; Mauduyt MA; Reyre J; Carles P; Serre G
Br J Cancer; 1999 Nov; 81(6):1059-65. PubMed ID: 10576665
[TBL] [Abstract][Full Text] [Related]
34. [Tumor markers in bronchus cancer].
Gasser RW; Denz H; Huber H
Wien Klin Wochenschr; 1989 Jul; 101(14):476-9. PubMed ID: 2549731
[TBL] [Abstract][Full Text] [Related]
35. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.
Liu L; Liao GQ; He P; Zhu H; Liu PH; Qu YM; Song XM; Xu QW; Gao Q; Zhang Y; Chen WF; Yin YH
Biochem Biophys Res Commun; 2008 Aug; 372(4):756-60. PubMed ID: 18514066
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
37. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
38. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of combination assay of tumor markers in primary lung cancer patients].
Hatakeyama S; Nagai A; Kioi S; Arakawa M
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Aug; 28(8):1053-8. PubMed ID: 2173801
[TBL] [Abstract][Full Text] [Related]
40. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
